

# The Life Sciences Voice

THE GEORGIA BIO INDUSTRY E-NEWSLETTER



## In This Issue:

GEORGIA BIO  
INNOVATION SUMMIT

EMORY SHARED  
RESOURCES

ACADEMIC SPOTLIGHT

CRO FOOTPRINT

EXECUTIVE INTERVIEW:  
DR. AJAY HOUDE

MEMBER SPOTLIGHT

MEMBER SAVINGS

NEW MEMBERS

JOB BOARD

UPCOMING EVENTS

EDITOR: JADA SELMA,  
SCIENTIFIC LIAISON  
& STUDIES COORDINATOR,  
METASYSTEMS GROUP, INC.;  
ELN VP MARKETING

## GaBio Innovation Summit Recap

In November, Georgia Bio welcomed more than 600 attendees and 110 industry experts to the first-ever virtual Georgia Bio Innovation Summit—and the timing couldn't have been better.

Starting the day after Election Day, we had three productive days of discussions about four critical challenges ahead: getting through the pandemic and economic crisis; tackling climate change; ending racial injustice; and standing up for science.

The key takeaway from the week: life sciences, including Georgia's thriving biotechnology industry, will play a key role in finding solutions for all of them.

Here's how.

### 1. Biotechnology is critical to building resilience.

COVID-19 has demonstrated the significant impact a pandemic can have on our health, our livelihoods, our food supply, and our economy, said **Everett Hoekstra, President of Boehringer Ingelheim Animal Health USA Inc.**, during the event kickoff.

This year has provided the life sciences industry with a clear vision of our collective purpose to serve mankind with lifesaving, lifechanging, and life enhancing health care, he continued.

“Now more than ever we’ve seen the importance of biotechnology in our everyday lives,” said **U.S. Secretary of Agriculture (and Georgia native) Sonny Perdue**.

With the national response to the pandemic and its impacts, we’ve seen “the critical role of innovation—specifically biological innovation—at play in mitigating supply chain risks and building resilience into our food and farming systems of the future,” continued Secretary Perdue.

So, how do we get there?

## **2. We need trust in science.**

While science has been progressing faster than ever before, “we still struggle with how the public views what we do,” said **Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO)**, during the opening keynote.

***“Political interference with science is not a one-party issue,” she said.***

“It is very tempting for politicians to think that it’s easy to tweak the science or push the science to meet their own political ends.”

This is why the scientific community must “stand up when we see a misuse or misappropriation of science,” and ensure we’re producing the highest-quality, well-tested science.

Biotechnology is “the industry that’s going to build the road for us to recover and grow. I just hope that our companies retain that focus, that I know they have,” she said, as well as “rebuild the pride in the work that we do.”

“How do we go back to having a society that trusts truth and trusts the data?” asked **Dr. Seth Berkley, CEO of Gavi, The Vaccine Alliance**, later in the week.

“Everybody can have their own opinions, but they can’t have their own facts.”

“With that trust in science, I think we can do a lot of healing,” he said.

## **3. We need collaboration.**

The global biotechnology industry has launched more than 800 research programs targeting COVID-19—including 11 vaccine candidates that have reached phase 3 clinical trials—in less than one year. How?

Speakers during a keynote on COVID-19 vaccines agreed: collaboration is key.

**Dr. Paul Burton, Chief Global Medical Affairs Officer for Janssen**

**Pharmaceuticals**, said partnerships—with government, with health authorities, with industry, and between companies large and small—have been critical to this unprecedented response.

“We are in competition against the virus—we’re not in competition with each other,” he said.

**Dr. Kathleen Toomey, Commissioner of the Georgia Department of Public Health**

credited collaboration with the state and local response, as well—working together “across districts and counties” with hospitals, health care providers, community organizations, and the business community to “keep people healthy at the same time we can keep the economy open” and communicate more effectively,

*“Even though, in many instances, we are competitors, when it comes to finding solutions for humanity, we can be a force,”*

added **Patty Fritz, VP of U.S. Corporate Affairs for UCB, Inc.**

**4. We need diversity and inclusion.**

Given COVID-19’s disproportionate impact on Black, African American, Hispanic, Latinx, and other communities of color, diversity and inclusion are key to overcoming the pandemic, as well—in particular, ensuring minority groups are represented in clinical trials.

To be successful in vaccine development,” continued Janssen’s Burton, “we have to provide transparency and confidence for ethnic minorities in clinical trials and underrepresented groups.”

This strategy will help us well beyond the pandemic, said **Dr. Alejandro Cané, VP, U.S. Medical and Scientific Affairs Lead at Pfizer Vaccines.**

But we shouldn’t stop at diversity in clinical trials, said **Dr. Clement Lewin, Associate Vice President, Head, BARDA Office and NV Stakeholder Engagement at Sanofi Pasteur.** We must eliminate socioeconomic or racial disparities in terms of access and acceptance of the vaccine, as well.

All of this requires the industry itself to be diverse and inclusive, too.

(It’s one of the reasons why Day 3 focused on D&I in the workforce and STEM education.)

*“We need to make sure we’re putting particular emphasis on those communities, and, again, having people who represent those communities who are spokespeople,”*

explained **Helene Gayle, MD, MPH, President & CEO of The Chicago Community Trust**, because these populations have “perhaps the most to gain because of the high burden of disease.”

"We want to make sure that those populations are getting the information that they need, but it's being done by institutions and individuals who are trusted, so we can build that trust," she said.

"We are going to travel at the speed of trust. It's not good enough to just have a vaccine if nobody wants to get vaccinated," she added.

### **Join the conversation on social media.**

Follow us on Twitter at @Georgia\_Bio and #GaBioSummit.



## **Emory Shared Resources Envisioning Health and Economy Together**

by B.R. Achyut, Ph.D. Scientist, Cancer Animal Models Shared Resource,  
Winship Cancer Institute of Emory University

Emory University is a top employer in Georgia, participating in the state's health advancements and economic development. Its highly ranked schools and outstanding performance in research, healthcare, and teaching put Emory at the forefront of academic health sciences in the Southeast. Currently, Emory and its partners manage all the critical technologies required for discovery and translation of basic research to clinical development.

These resources are available to academic and commercial investigators across Georgia through the Emory Integrated Core Facilities (EICF).

The EICF arose from the vision of **Dr. Michael E. Zwick**, Professor of Human Genetics and Pediatrics, Associate Dean for Research in the School of Medicine and Associate Vice President of Research for the Woodruff Health Sciences Center.

The EICF plays a critical role in supporting research and development by supporting highly trained staff with the expertise necessary to operate cutting-edge instrumentation. These facilities support many aspects of Emory's research mission that include recruiting and retention, grants and centers, education, collaboration among investigators, and the sharing of knowledge in order to speed up scientific advancements.

**"The idea of making this a statewide resource began with a goal of learning and sharing the resources that bridge the gap by building partnerships among collaborative Georgia institutions," said Dr. Zwick.**



He first reached out to the University of Georgia and established a partnership that enables investigators to use shared resources with internal rates. Later, this led to the establishment of the statewide Georgia Core Facilities Partnership. Academic institutions represented include Augusta University, Clark Atlanta University, Emory University, Georgia Institute of Technology, Georgia State University, Mercer University, Morehouse School of Medicine, and the University of Georgia. Currently, over 95 core facilities in all eight academic institutions are included in this partnership. The **Georgia Research Alliance** hosts a searchable website named the [GRA Core Exchange](#), where individuals can discover these resources.

These statewide partnerships give every investigator in Georgia access to high-performing technologies and brilliant scientific expertise. **"Now, we are the first in the nation with statewide coverage of core facilities in the form of shared resource consortium,"** added Dr. Zwick. Looking into the future, Emory hopes to expand core facilities with the upcoming HSRB-II building, which will have designated BSL-3 facilities to deal with infectious disease and pandemic solutions.

All core facilities communicate at regular intervals. The Southeastern Association of Shared Resources ([SEASR](#)) meeting and the annual [Core Day](#) are a couple of opportunities to exchange ideas and improve partnerships.

Because of increasing health and clinical demands in Georgia, core facilities (often also referred to as shared resources) offer external rates for private companies, contract or collaborative research organizations (CROs), and pharmaceutical industries. The unique platforms housed within core facilities can provide capabilities to startup companies that would be expensive to recreate. Zwick emphasizes the external organizations need only contact the core facilities via their website to determine how they might access services. At the same time, to enhance efficiency, Emory has pursued outsourcing of core services for nearly eight years, especially in the area of genomics and other valuable commodity services, to companies in Georgia and elsewhere.

The Winship Cancer Institute is also a strong supporter of shared resources at Emory. Currently, [Winship](#) supports a total of 11 core facilities within Emory. Winship cores support four cancer research programs, assisting in pre-trial, preclinical and clinical trials, and post-trial analysis.

The Emory integrated shared resources that are intimately involved in Winship's goals are genomic, proteomics, and cellular imaging.

Winship shared resources such as the core facilities of Biostatistics, Bioinformatics and System Biology, Cancer Tissue and Pathology, Cancer Animal Models, Winship Research Informatics, and Flow Cytometry, have a fundamental role in fulfilling the needs of Winship researchers.



The newly added Immune Monitoring core provides high dimensional mass cytometry analysis for ongoing clinical trials at Winship. The population-based Intervention Development, Dissemination, and Implementation shared resource has access to expertise in behavioral science research methods and supports intervention research at all stages of development.

Winship's shared resources are the home of world-class technology. The Cellular Imaging core recently acquired through an NIH grant Georgia's first [3D STED microscope](#), a million-dollar high-end instrument with super-resolution and real-time images at the nanoscale range. Also, the Cancer Animal Models core can deliver clinical-grade imaging using [IVIS](#) and [SmART+](#) instrumentations.

Winship shared resources and services are tightly aligned with National Cancer Institute guidelines and the research needs of our cancer investigators. **Dr. Adam Marcus**, who is the Associate Director for Basic Research and Shared Resources, also emphasized the potential collaboration with pharmaceutical companies and CROs.



Since cancer is under intense investigation during the pandemic, Winship is part of critical projects involving patients' outcomes and disparities regarding future risks. The shared resources will always be fulfilling the demands of virus testing or vaccine development, through collaboration with the academic or non-academic partners.

"We are actively participating in population-based interventions, and molecular profiling of cancer and COVID-19-related research with the help of the Winship shared resources," Dr. Marcus was proud to report.

***"There is potential to partner with pharma and CROs to help drive health and economic benefits for the Georgia community."***



Such partnerships could be a bridge for the growing life science industry in the Atlanta area. There has been a record growth of startup companies. Now is the right time to pluck the low hanging fruits.

## Academic Spotlight: Georgia Clinical & Translational Science Alliance (CTSA)

by: Paul Snyder, Vice President - Healthcare,  
write2market

The State of Georgia is blessed with thousands of scientist researchers including clinicians and engineers whose work is the genesis of life science innovation. Founded in 2008 through funding from the NIH's [National Center for Advancing Translational Sciences](#), The Georgia Clinical & Translational Science Alliance leverages diverse scientific expertise from Emory University, Morehouse School of Medicine, Georgia Tech and the University of Georgia "to accelerate clinical and translational education, research, and community engagement to impact health in Georgia and beyond.

The alliance's cornerstone activities include training the next generation of clinical investigators, translating research and observations in the lab, clinic and community into interventions that improve population health and engaging communities in clinical research efforts.

Since its inception, the Georgia CTSA has supported more than 1,500 investigators in over 300 research areas, primarily biostatistics, epidemiology and informatics. It has awarded \$14 million in 350 pilot grants that subsequently received \$134 million in follow-on funding, a 10:1 return on the alliance's translational research investments.

## Training the Translational Workforce

The Georgia CTSA Research Education programs include: Master of Science in Clinical Research, KL2 Mentored Clinical and Translational Research Scholars Program for junior faculty, TL1 Core for pre- and post-doctoral researchers and a Certificate Program in Translational Research.

"Clinical training enhanced my perspective as a researcher, yielding more nuanced, patient-centered research questions aimed at achieving health equity." - Patrick Carriere, Ph.D., 2018 Graduate, Morehouse School of Medicine and 2016 graduate of the Georgia CTSA Certificate Program in Translational Research.

Researchers completing one of Georgia CTSA's education programs have received more than \$21 million in grant funding to date.

## Translating Research

[Translational science](#) turns "observations in the laboratory, clinic, and community into interventions that improve the health of individuals and the public — from diagnostics and therapeutics to medical procedures and behavioral changes."

From flu vaccines capable of protecting against multiple virus strains in a single dose, to 3D printed medical devices and bio printing for tissue mimics, informatics capable of increasing candidate patients for clinical trials and beyond Georgia CTSA funded investigators are demonstrating the ability to successfully carry research from the bench to market and patient care.

In one example, Georgia CTSA funded a clinical assessment of CellScope OTO (™) co-developed by Dr. Wilburn Lam.

Dr. Lam is associate professor of pediatric hematology and oncology for the Emory School of Medicine and associate professor of the Wallace H. Coulter Department of Biomedical Engineering, a joint venture of Emory University and Georgia Tech. CellScope OTO is a smartphone otoscope that enables remote diagnosis of ear infections.

In another example, Georgia CTSA Investigators Igbo Ofotokun and Anandi Sheth received a \$17 million NIH grant a \$7.4 million SCORE grant for their research efforts to understand and reduce the impact of chronic health conditions - including heart, lung, blood and sleep disorders - that affect people living with HIV.

### Engaging Community

Life science innovation and translation is not geographically dependent. The addition of the University of Georgia to the CTSA with campuses state-wide further expands the organization's reach into underserved rural communities with very real population health concerns.

Its collaboration with community-based organizations builds partnerships with academic institutions for pilot projects, research and dissemination of community-relevant findings.

Through programs like the Biennial Community Engagement Research Program Forum, Community Engagement Grant Writing Academies and the [2020 Southeast Regional Clinical and Translational Science Alliance Conference](#), "We aim to increase the capacities of our community partners and academic research projects that better address community health and wellness needs," says Tabia Henry Akintobi, Ph.D., MPH and Director, Community Engagement Program, Morehouse School of Medicine.

**Stay connected with Georgia CTSA on [Twitter](#).**

## CRO Footprint Enhancing the Life Science Research Framework in Georgia

by B.R. Achyut, Ph.D. Scientist, Cancer Animal Models Shared Resource, Winship Cancer Institute of Emory University

One of the recently founded collaborative research organizations (CRO), [Radyus Research](#), led by **Dr. Marta New**, could be the first icebreaker as a virtual CRO in Atlanta. Radyus is innovating the CRO model by subcontracting preclinical drug testing with top core facilities across the region, and they are eager to start bringing industry clients to Emory's shared resources. Therapeutic areas are a good fit for Emory as well, as Radyus is primarily focusing on oncology, immunology, metabolic disorders, infectious diseases, and neuroscience.



Dr. New is fascinated by the level of collaboration and resource sharing across the Georgia universities. This wealth of resources has encouraged her to set up Radyus here in Atlanta to replicate what we see in Boston and San Francisco areas. She feels Georgia is a world-class academic hub represented by Emory, Georgia Tech, UGA, and others. High-quality science and entrepreneurial spirit will enable the growth of biotech startup culture in the Atlanta area.

***"There is a strong opportunity to build an ecosystem where all partners can grow," said Dr. New.***



Such symbiotic culture should attract more investors and biotech companies for product development as well as pharma buyers, she added.

"And Georgia universities are well-positioned to lead the way. With strong R&D, motivated tech transfer offices, and Emory's core facilities network in place, they can amplify alliances with small or big pharma for timely drug development," she suggested.

Radyus CRO wants to be that bridge between universities and industry.

***"We see building a long-term relationship with academia in the Atlanta area as a critical step in growing the local biotech ecosystem. We can drive more business through the shared resources, help local academic startups as clients and hire and train PhDs interested in industry positions as part of our growing organization".***

Currently, Dr. New is exploring how Emory's core facilities can support the long-term goals of Radyus in Atlanta. It would be interesting to see how Emory - CRO collaboration could benefit each other within the partnership, staffing, financial, and legal framework. Interacting with Emory's core facilities would set up an example for other academic institutions in Georgia. More importantly, it would show how we, as partners, could boost health and economic development in Georgia similar to what has been seen in Boston and San Francisco.

## Executive Interview: Dr. Ajay Houde, (Ph.D., MBA), CEO and Co-founder, TGen Tech

By: Brianna Chilton, M.S., Ph.D. Candidate, ELN Chair

### **With a background in academia and polymer chemistry, how did you make the transition in your career into the medical devices industry?**

My background is in polymer chemistry. For my Ph.D., I focused on using polymers for separating gases. For example, in natural gas processing, there is a high amount of carbon dioxide you want to separate out to increase the heating value of the gas. There was a lot of need to come up with a new polymer equative to selectively separate out carbon dioxide that can maintain the high pressure on the other side of the drill.

I came to American in 1991 and had a chance to work with one of the pioneers in polymer membranes for gas separation, Dr. S. Alexander Stern. During my 4 years as a post-doc at Syracuse University, I was able to continue my passion of making highly effective polymeric membranes for gas separations. We got a patent and several manuscripts published in peer-reviewed scientific journals.

To my knowledge, to this day, that technology is still being used in a commercial application for gas separation.

Having been employed in academia for 4 years and learning how long it took to bring innovative solutions to the market,



I became a little impatient. So, I decided to join industry. While working for a medium-sized company, I started my career as a process engineer using my polymer background to make specialty coatings for various applications. I got to see what it takes to make bench-scale products become commercially feasible via working with bigger corporations like 3M, Fuji, and Kodak. We were producing specialty products while managing the program for various industries. I started understanding how small companies work and what it means to collaborate with companies that have a 5-year to 10-year plan. I came to Atlanta in 1999 and started working at Kimberly-Clark, a fortune 500 company. This is where I was exposed to healthcare medical devices and technologies.

**From here, it seems like your professional focus switched to the larger picture and business aspects of medical devices. How were you able to accomplish that?**

Since joining industry in 1995, I have been very passionate and involved in understanding what the customer/patient wants, developing new solutions, and launching products and solutions into the market. I worked at Kimberly-Clark Healthcare, which then became Halyard Health in 2014. I had a great chance to be close to what happens in operating rooms and ICUs and to see what it means from the physician's or caregiver's prospective to treat patients. More than anything, I was able to see all kinds of surgeries all over the world. It gave me a good understanding of how you identify what is not working and how you come up with new, meaningful solutions to solve customer pain points. Slowly then, I got involved more into understanding the company culture and investing activities. Then, considering the company's technological advancements and competitor activities, I contemplated on what the R&D strategy should look like. Furthermore, I brainstormed about what the company wants to look like in the next 3, 5, 10 years, therefore forming a strategical outlook.

While the technical background and industry experience are great to have, it was the business and marketing aspects I really needed to learn. So, I went back to college and got my MBA while working full time. This is what really helped me to continue to contribute and to grow at higher professional levels. In 2017, I decided to leave Halyard Health.

I realized there were a lot of markets, particularly the pediatric market, that were not getting the best of the best possible solutions. Being passionate about innovation and making a positive difference, my friend and I decided this was the time for us to do something about some of the problems in the pediatric field. Therefore, we decided to start the company TGen Tech.

### **What made you decide on cardiovascular pediatrics?**

Cardiovascular disease is one of the leading causes of morbidity in the United States. Particularly, 1.3 million children are born each year globally with congenital heart defects. Nearly 5% of these children don't survive the first year, while the remaining 95% of children have to go through multiple complex and expensive surgeries due to the fact that current commercial devices are inadequate, cause calcification and thrombosis, and are eventually rejected by the body. According to a survey conducted in 2018 by the FDA, large corporations are not investing in addressing the clinical needs in the pediatric market due to less than desirable return on investment.

My co-founder and a friend for more than three decades, Dr. Vyavahare, has been researching in the cardiovascular area for nearly 25 years. Considering the unmet need and access to a breakthrough technology that can address the clinical and economical challenges mentioned above led us to focus on the pediatric cardiovascular devices market.

**With TGen Tech having been up and running for around 2 years, what would you say are your larger challenges now?**

I would not call them challenges. There is always some opposition you face. The biggest opposition we have is how do we quickly commercialize our breakthrough technology that can have a positive effect on children's health outcomes. Every year, there are 40,000 children born in the United States and 5% of them do not see their first birthday. There are many children who must go through multiple surgeries in throughout their entire life. (A) This is very expensive. (B) Every time you do a surgery, there is potential something could go wrong, especially when you have to open the heart and fix something inside. You can imagine how complex cardiac surgery is. Furthermore, think of it emotionally from the prospective of the parent or the patient. It is a very challenging process. The opportunity we have is to make sure the device we are working on continues to be safe, effective, and, more than anything, quickly adopted by physicians to make a difference in the lives of millions of patients.

**Do you have an idea of how your company fits into the growing life sciences industry in Georgia?**

What I can tell you from being in this great state for the last 21 years and having worked in the healthcare industry, there continues to be a need for meaningful solutions, specifically in the pediatric market.

Through 2017-2018, the FDA and NIH conducted a survey of several thousand positions trying to understand their unmet needs. Two-thirds of the participants cited a need for new medical devices. Over 90% of them said there needed to be new or improved medical devices<sup>1</sup>. Over 70% of them stated that there is this need due to big companies not investing in bringing innovative products to the market<sup>1</sup>. Companies do not see the pediatric market to be large enough to meet the criteria for investing. I understand how the investment decisions are made in large corporations. You look at every program, every initiative and decide to invest or not. This is where I believe the small companies can work to bring these solutions to the market here in Georgia.

**How does COVID-19 seem to be affecting TGen Tech?**

Great question. At our end-of-the-year planning meeting in December 2019, we set up all our key milestones through the middle of 2021. We were cruising along until the middle of March.

My co-worker and I were travelling to meet with various institutions and had heard about what was happening in Italy, Brazil, India, and Korea. I honestly never thought we would be in the situation we are in now with COVID-19. Once we returned home, we started talking with our coworkers and realized things were getting very serious by mid-March. We had to readdress what was going on. We are a small company and are leveraging a lot of outside vendors to complete work for us.



People were not able to come in to complete the pre-commercialization work: marketing, manufacturing, competitive testing, etc. I was not even going to ask people to go in to do this work. For me personally, I have a family and I wanted to keep them as well as my coworkers' families safe.

Therefore, we had to readjust. This is the beauty of being a small company though; we moved to plan B. We started focusing on the items that can be done remotely without coming into the office, i.e. a lot of paperwork. We got approval from the FDA for our device, and we worked on submitting additional grant proposals. We also utilized the down time to brainstorm about who else we can collaborate with, and now we have two more companies we are going to be working with. So, yes, there have been some pains that we have had to deal with, and we have had to make some course corrections. But we have also been able to do some different things we might not have done without this unexpected interruption in our normal operations.

### **What personally have you been doing during this time to take your mind off your work?**

One of the things I have been actively engaged and passionate about is serving the community. Because of my healthcare background, there is an international organization called SEWA that I have gotten involved with. We have been making facemasks, and I put together training to instruct numerous volunteers on how to make facemasks.

We use these to help provide PPE to hospitals, jails, police precincts, fire stations, grocery stores, and various people. Every weekend, I used to go with volunteers to give food to hospital workers. Also, since international students have been affected by COVID-19, I am currently involved in working with hundreds of volunteers nationally to provide various resources for career transitions, including mentoring, training, workshops, etc. to help them get placed into jobs in their respective fields. This is how I have been keeping busy during the COVID-19 pandemic.

### **Is there anything you would like to mention that I did not ask about?**

I would like to recognize many people. As a small company, I could not do this without leveraging the biotech ecosystem. Along with various research institutions and vendors, I would like to acknowledge [Tech Alpha](#) and [ATDC](#) for their resources and guidance. Also, thanks to my family, friends, and co-workers for their unconditional support and encouragement.

References 1. 2018 FDA/NCATS Report on Unmet Medical Device Needs for Patients with Rare Diseases | FDA. <https://www.fda.gov/industry/humanitarian-use-device-hud-designation-program/2018-fdancats-report-unmet-medical-device-needs-patients-rare-diseases>.

## New Member Spotlight

nexAir offers the specific and highest quality scientific gases, gas regulation equipment, and dry ice for your needs when and where you need them. We deliver the knowledge, ideas, and advice you should have to smartly source the gases for your organization on an ongoing basis. nexAir's scientific gases and active partnership empowers you to have more confidence in how you conduct research and create new solutions each and every day.

Please feel free to contact Blake Quigley at 404-713-7150 (blake.quigley@nexair.com) for all your scientific needs.

## Purchasing Program: Enhanced Member Benefits, Saving Money and Time, Helping You Help Patients

Through Georgia Bio's [Purchasing Program](#), our members have access to programs and services negotiated by Georgia Bio and BIO, offered at favorable rates and terms to save your company money. Through our affiliation with BIO, Georgia Bio is part of the largest cost-savings program for the life science industry with the purchasing power of over 2,800 biotech companies. Our group discounts are for members only and your membership is the gateway to this purchasing power to save your company critical resources.

For more information on how you can sign up for these member discounts and save your working capital, contact Kristina Forbes at [kforbes@gabio.org](mailto:kforbes@gabio.org).



## Post to the Job Board!

Georgia Bio encourages companies to post career opportunities or internships [here](#).

This job board is custom tailored for the Life Science industry, which means we attract the most qualified professionals in Georgia.

[Discover current opportunities on the job board.](#)

## Welcome to our New Members

- [Agnes Scott College](#)
- [Ares Immunotherapy](#)
- [Axion Biosystems](#)
- [BIO](#)
- [BiotechExec](#)
- [Brady Ware & Company](#)
- [Commissioning Agents, Inc. \(CAI\)](#)
- [Calectin Therapeutics](#)
- [CCMI](#)
- [Gerresheimer](#)
- [Gilead](#)
- [GRAIL](#)
- [HERA laboratory planners](#)
- [Kimera Labs](#)
- [Largent Health](#)
- [Micron Biomedical](#)
- [nexAir LLC](#)
- [Pain Care Labs](#)
- [PJ Fitzpatrick Consultants](#)
- [Radyus Research](#)
- [Relish Marketing](#)
- [Select Gases](#)
- [SLAM Collaborative](#)
- [SpeciCare](#)
- [Verge Scientific Communications](#)
- [Vernay](#)
- [Vertex](#)

## Upcoming Events

- [Redefining Early Stage Investments \(RESI\) Conference Series](#): Jan 11, 2021—Jan 13, 2021
- [Biotech Showcase™ Digital 2021—13th Annual International Partnering Conference](#): Jan 11, 2021—Jan 15, 2021
- [The Launch of: Women in Global Health – Georgia U.S.A.](#): Jan 13, 2021
- [The 16th Annual Non-Dilutive Funding Summit](#): Jan 13, 2021
- [BIO & Georgia Bio Briefing: Developing and Distributing a COVID-19 Vaccine](#): Jan 14, 2021